knowledge -WSS

knowledge

author：hotspot 2025-10-02 11:08:10 - browse：1281

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Pharmacists can make shortage drugs, but at what cost?

entertainment

knowledge

WSS

Beam Therapeutics to lay off 20% of its staff, re

Hospital price transparency does save money, advocate argues

The effects of a landmark ruling on DNA ownership are becoming clearer

Senate committee scrutinizes Medicare Advantage brokers

As health system earnings go up, health insurance stocks go down

FDA warns J&J's Abiomed: We will regulate your software

focus

knowledge

leisure time

Moonlake's readout produced a cash windfall. Risks remain

STAT Readout Newsletter: Today's biggest biotech updates

Walensky prepares to leave CDC — and Congress — behind

Crowdfunding for medical bills sidesteps core problem, author says

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: Biotech founders on deal

Activists slam private health insurers over coverage restrictions

STAT Summit: Biotech founders on deal

At least 13 dead in Texas as scorching temps continue

AI for drug discovery: Experts on separating hype from reality

hotspot

The creative science of coining drug names

Empower primary care with adequate payments and technology

The creative science of coining drug names

The explosion of genetic testing requires a new approach

HHS's proposed rule does nothing to address the climate crisis

Class action alleges UnitedHealth concealed DOJ probe

entertainment

explore

knowledge

knowledge